News & Events CTI and Bexion Pharmaceuticals To Present as Part of Kentucky Life Sciences Council’s Derby Partnering Summit

CTI and Bexion Pharmaceuticals To Present as Part of Kentucky Life Sciences Council’s Derby Partnering Summit

May 3, 2016

CTI Clinical Trial and Consulting Services and Bexion Pharmaceuticals To Present as Part of Kentucky Life Sciences Council’s Derby Partnering Summit 

FOR IMMEDIATE RELEASE [Cincinnati, OH ~ May 3, 2016]

CTI’s Chief Executive Officer, Timothy J. Schroeder, and Bexion’s Chief Executive Officer, Ray Takigiku, PhD, will present as part of the Kentucky Life Sciences Council’s Derby Partnering Summit, taking place May 5-6 in Covington, Kentucky. The Derby Partnering Summit’s goal is to bring together students, advocates, entrepreneurs, business leaders, academics and researchers from disciplines across the life sciences industry. The pair will speak about their locally-based collaboration on Bexion’s groundbreaking oncology trial, with an emphasis on the resources available for local life-science companies in the Greater Cincinnati area and throughout the Midwest.

“We're thrilled to be speaking as part of the Derby Partnering Summit to bring awareness to regional life sciences,” according to Schroeder. “All the components necessary for successful drug/device development and commercialization are present in this region – from innovative financing and major cutting-edge academic institutions to knowledgeable executive leadership and robust, experienced pharmaceutical services, including clinical research organizations and manufacturing firms. Despite being a global service provider working on five continents, CTI finds some of the most exciting innovations are occurring right here.”

“It is Bexion’s honor to be participating in the keynote luncheon address at the second annual Derby Partnering Summit,” stated Takigiku. “From original idea to clinical trials, Bexion has greatly benefitted from the talented resources available to us in this region. Bexion is committed to advance our region's economic vitality by not only our significant progress in the fight against cancer, but also by helping to cultivate a strong bioscience and innovation ecosystem.”

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hematology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit

Media Contact: Allison Schroeder ●513.598.9290 ●

About Bexion Pharmaceuticals

Bexion Pharmaceuticals is a privately-held biotech company focused on the development and commercialization of innovative cures for cancer. Bexion’s first-in class biologic, BXQ-350, has demonstrated selective tumor targeting with the potential for clinical efficacy in a broad range of cancers. In 2013 the NCI awarded Bexion a prestigious "Bridge Award" of $3MM to support testing of BXQ-350 in the clinic. In February 2015, the FDA granted Bexion Orphan Drug status for Saposin C, the active ingredient in its proprietary drug BXQ-350 for the potential treatment of glioblastoma multiforme (GBM), a type of brain cancer.

Media Contact: Margaret van Gilse ●


Original Press Release

Subscribe to our mailing list

* indicates required